Hol dir die App Get the App
⭐️⭐️⭐️⭐️⭐️
44 Bewertungen
Zur App
DAX 25.325,00 -0,76% Dow Jones 52.063,00 -0,70% MDAX 31.531,80 -1,50% Nikkei 225 64.035,00 -0,18% S&P 500 7.595,03 -0,57% STOXX Europe 50 6.256,50 -0,67% Nasdaq 100 29.112,20 -1,03% Bitcoin 77.308,53 USD -1,02% Gold 138,76 USD -1,91% EUR/USD 1,16 USD -0,16%
DAX 25.325,00 -0,76% Dow Jones 52.063,00 -0,70% MDAX 31.531,80 -1,50% Nikkei 225 64.035,00 -0,18% S&P 500 7.595,03 -0,57% STOXX Europe 50 6.256,50 -0,67% Nasdaq 100 29.112,20 -1,03% Bitcoin 77.308,53 USD -1,02% Gold 138,76 USD -1,91% EUR/USD 1,16 USD -0,16%
+49 (0) 172 414 333 6
Wertpapiere

Aktie DE000A2P4LJ5

PharmaSGP Holding SE

28,80 €

  • 0,00 €
  • |
  • 0,00 %

Your browser does not support the canvas element.

  • Aug.
  • Sept.
  • 28.79
  • 28.80

ERTRÄGE

Warnung: Die Dividende wurde um 35,1% gekürzt auf 0,02 € pro Aktie. Dies könnte eine strategische Entscheidung sein oder auf veränderte finanzielle Prioritäten hinweisen. Aktionäre sollten prüfen, ob dies ein isolierter Rückschlag oder ein Zeichen struktureller Probleme ist.

0,021 €

Jährliche Dividende

0,073 %

Rendite

  • 0,032 €

    Juni

-35,08 %

Dividenden-Wachstum

  • 23

  • 24

  • 25

  • 26

  • 27

1,49 %

Ausschüttungsquote

  • A

    1 %
  • 99 %

    G

  • A

    1 %
  • 99 %

    OCF

Historische Dividenden

    • 1,87 %
    • 0,45 €
    2022
    • 1,80 %
    • 0,49 €
    2023
    • 5,91 %
    • 1,36 €
    2024
    • 0,18 %
    • 0,05 €
    2025
    • 0,11 %
    • 0,03 €
    2026

UNTERNEHMEN

122,1 Mio. €

Umsatz

  • 19,7 Mio.

    NG

  • 0,00

    F&E

  • 110,6 Mio.

    BG

  • 122,1 Mio.

    U

2,75 %

Umsatz-Wachstum

  • 22

  • 23

  • 24

  • 25

  • 26

19,7 Mio. €

Nettogewinn

  • 57,0 %

    ROE
  • 16,1 %

    ROS
  • 15,9 %

    ROA
  • 32,3 %

    GPM

22,2 Mio. €

Operativer Cashflow

  • FCF

    93 %
  • 7 %

    CapEx

34,5 Mio. €

Eigenkapital

  • EK 28 %
  • 72 % FK

91

Mitarbeiter

  • 1,3 Mio. €

    Umsatz / MA
  • 216.549,5 €

    Gewinn / MA

KGV

7,28 €

KBV

4,15 €

KCV

6,95 €

KUV

1,18 €

EV/EBITDA

5,06 €

EV/EBIT

7,09 €

EV/FCF

9,66 €

EV/Umsatz

1,63 €

EnterpriseValue

199,5 Mio. €

Eigenkapitalrendite

57,04 %

Umsatzrendite

16,14 %

EBIT-Marge

23,06 %

EBITDA-Marge

32,30 %

Kapitalumschlag

0,98 €

Gesamtkapitalrendite

15,89 %

Eigenkapitalquote

0,28 €

Fremdkapitalquote

0,72 €

Verschuldungsgrad

2,59 €

Dyn. Verschuldungsgrad

4,03 €

Sachinvestitionsquote

-0,004 €

Anlagendeckungsgrad 1

1,78 €

Anlagendeckungsgrad 2

0,64 €

Liquidität 1. Grades

1,18 €

Liquidität 2. Grades

1,73 €

Liquidität 3. Grades

2,20 €

Dividende pro Aktie

0,05 €

Dividendenrendite

0,20 %

Ausschüttungsquote

1,49 %

Buchwert pro Aktie

5,87 €

Cashflow pro Aktie

3,77 €
Stand: 31.03.2025 TTM

Fakten

  • Sitz

    Deutschland

  • Hauptsitz

    Gräfelfing

  • Börsengang

    19.06.2020

  • Ausstehende Aktien

    5,88 Mio.

  • Mitarbeiter

    91

  • Währung

    EUR

  • Sektor

    Gesundheitswesen

  • Industrie

    Drug Manufacturers - Specialty & Generic

  • Börse

    XETRA

  • Ticker

    PSG.DE

  • Webseite

    pharmasgp.com

Aktie

Unternehmensinfos

PharmaSGP Holding SE manufactures over-the-counter drugs, and other healthcare products in Germany. The company's pharmaceutical products include Baldriparan for the treatment of sleep disorders; Spalt, Formigran, and Kamol massage cream for the treatment of different pain conditions; RubaXX pharmaceutical drops for the treatment of rheumatic pain in bones, tendons, and muscles; Restaxil pharmaceutical drops for the treatment of nerve pain in neck and back; Fulminan, a beauty drink for problems in areas, such as eye area, buttocks, or thighs; DESEO pharmaceutical drops for sexual weakness; Neradin, a drug for sexual dysfunction; and TAUMEA, a drug for the treatment of vertigo. It also offers products for the treatment of chronic indications, including pain and other age-related ailments. The company sells its products through pharmacies and wholesalers. It exports its products to European countries comprising Austria, Italy, Belgium, Spain, and France. The company was founded in 2012 and is based in Gräfelfing, Germany.
PharmaSGP Holding SE manufactures over-the-counter drugs, and other healthcare products in Germany. The company's pharmaceutical products include Baldriparan for the treatment of sleep disorders; Spalt, Formigran, and Kamol massage cream for the treatment of different pain conditions; RubaXX pharmaceutical drops for the treatment of rheumatic pain in bones, tendons, and muscles; Restaxil pharmaceutical drops for the treatment of nerve pain in neck and back; Fulminan, a beauty drink for problems in areas, such as eye area, buttocks, or thighs; DESEO pharmaceutical drops for sexual weakness; Neradin, a drug for sexual dysfunction; and TAUMEA, a drug for the treatment of vertigo. It also offers products for the treatment of chronic indications, including pain and other age-related ailments. The company sells its products through pharmacies and wholesalers. It exports its products to European countries comprising Austria, Italy, Belgium, Spain, and France. The company was founded in 2012 and is based in Gräfelfing, Germany.